NCT00344149View on ClinicalTrials.gov

Rituximab as Second Line Treatment for ITP

PHASE3CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Immune Thrombocytopenia (ITP)
Interventions
DRUG

Rituximab (Mabthera)

I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks

Trial Locations (1)

1603

Østfold Hospital Trust in Fredrikstad and National hospital in Oslo, Fredrikstad and Oslo

All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

collaborator

South-Eastern Regional Health Authority

UNKNOWN

lead

Ostfold Hospital Trust

OTHER

NCT00344149 - Rituximab as Second Line Treatment for ITP | Biotech Hunter | Biotech Hunter